

Title	ALIF-1 EBOO SAFE: treatment of coronary artery diseases
Agency	MaHTAS, Health Technology Assessment Section, Medical Development Division, Ministry of Health Malaysia Level 4, Block E1, Parcel E, Presint 1, Federal Government Administrative Center, 62590 Putrajaya, Malaysia Tel: +603 88831229, Fax: +603 88831230; htamalaysia@moh.gov.my, www.moh.gov.my
Reference	Technology Review Report, 016/2011, online: http://www.moh.gov.my/technology_reviews/213

Aim

The objective of this technology review was to assess the safety, efficacy/effectiveness and cost effectiveness of Alif-1 EBOO SAFE® in the management of coronary artery diseases

Conclusions and results

Insufficient high quality scientific evidence was found on the effectiveness/efficacy and safety of Alif-1 EBOO SAFE® in the management of coronary artery diseases. Although as a single machine, the ultrafiltration technology (claimed as similar technology with SAFE) has been established for many years, the new device represents a different technology that requires thorough assessment, particularly in the context of managing coronary artery disease.

Methods

Electronic databases were searched, they included PubMed, 1990-2011 EBM Reviews – Cochrane Databases of Systematic Reviews, 1990-2011 EBM Reviews – Cochrane Databases of Controlled Trial, National Horizon Scanning, INAHTA and the FDA website, for published reports. No limits were used. Additional articles were identified from reviewing the bibliographies of retrieved articles and information from the Organization of Medical Ozone Therapies in Malaysia.

Further research/reviews required

More clinical research and studies should be carried out at various local clinical settings to validate the equipment performance and to ascertain the safety, effectiveness / efficacy and cost effectiveness of the device.

Written by

Maharita AB, MaHTAS, Malaysia